1. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
   Andrew J. Wilson et al, 2018, Gynecologic Oncology CrossRef
2. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
   Garrett W. Rhyasen et al, 2018, PLoS ONE CrossRef
3. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells
   Majid Momeny et al, 2018, Anti-Cancer Drugs CrossRef
4. Therapeutic Inducers of Apoptosis in Ovarian Cancer
   Mudra Binju et al, 2019, Cancers CrossRef
5. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
   Manoela Tiago et al, 2020, Br J Cancer CrossRef
6. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
   Shariska Petersen et al, 2020, Gynecologic Oncology CrossRef
7. Clinical perspectives of BET inhibition in ovarian cancer
   Angeliki Andrikopoulou et al, 2021, Cell Oncol. CrossRef
8. Exploiting epigenetic dependencies in ovarian cancer therapy
   Aisling Y. Coughlan et al, 2021, Int. J. Cancer CrossRef
9. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
   Ana Luiza Drumond-Bock et al, 2021, Mol Cancer CrossRef
10. Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric BRD4 inhibitor/nitric oxide-donator
    Yuehua Zhang et al, 2022, European Journal of Medicinal Chemistry CrossRef
11. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
    Marcos Quintela et al, 2023, Clin Epigenet CrossRef
12. Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma
    Hillary P. Esplen et al, 2023, Life CrossRef
13. Anticancer Effects of BRD4 Inhibitor in Epithelial Ovarian Cancer
    Yeorae Kim et al, 2024, Cancers CrossRef
14. The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer
    Angeliki Andrikopoulou et al, 2024, Cancers CrossRef